Mason W Freeman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4911444/publications.pdf

Version: 2024-02-01

28 papers 4,314 citations

430754 18 h-index 26 g-index

28 all docs

28 docs citations

28 times ranked

5468 citing authors

#	Article	IF	CITATIONS
1	Scavenger Receptors Class A-I/II and CD36 Are the Principal Receptors Responsible for the Uptake of Modified Low Density Lipoprotein Leading to Lipid Loading in Macrophages. Journal of Biological Chemistry, 2002, 277, 49982-49988.	1.6	826
2	Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nature Medicine, 2004, 10, 416-421.	15.2	579
3	The role of PPAR-Î ³ in macrophage differentiation and cholesterol uptake. Nature Medicine, 2001, 7, 41-47.	15.2	476
4	Scavenger Receptors in Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1702-1711.	1.1	461
5	Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease. JAMA - Journal of the American Medical Association, 2015, 314, 151.	3.8	370
6	Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. Journal of Clinical Investigation, 2005, 115, 2192-2201.	3.9	324
7	A CD36-initiated Signaling Cascade Mediates Inflammatory Effects of β-Amyloid. Journal of Biological Chemistry, 2002, 277, 47373-47379.	1.6	302
8	The induction of macrophage gene expression by LPS predominantly utilizes Myd88-independent signaling cascades. Physiological Genomics, 2004, 19, 319-330.	1.0	270
9	Divergent Response to LPS and Bacteria in CD14-Deficient Murine Macrophages. Journal of Immunology, 2000, 165, 4272-4280.	0.4	205
10	Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. Kidney International, 2015, 88, 1427-1433.	2.6	90
11	An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates. Cell Host and Microbe, 2021, 29, 1437-1453.e8.	5.1	53
12	Functional Changes in Scavenger Receptor Binding Conformation Are Induced by Charge Mutants Spanning the Entire Collagen Domain. Journal of Biological Chemistry, 1998, 273, 19592-19601.	1.6	48
13	Activation of signaling pathways by putative scavenger receptor class A (SR-A) ligands requires CD14 but not SR-A. Biochemical and Biophysical Research Communications, 2003, 310, 542-549.	1.0	48
14	Longâ€term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensinâ€converting enzymes/angiotensin receptor blockers: results from AMETHYSTâ€DN. ESC Heart Failure, 2018, 5, 592-602.	1.4	45
15	Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD. American Journal of Kidney Diseases, 2019, 74, 328-337.	2.1	43
16	Atherosclerosis and innate immune signaling. Annals of Medicine, 2005, 37, 130-140.	1.5	37
17	In Vitro–Differentiated Embryonic Stem Cell Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1647-1654.	1.1	32
18	A 96â€week, multinational, randomized, doubleâ€blind, parallelâ€group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 2496-2504.	2,2	24

#	Article	IF	CITATIONS
19	Mutations in Signal Sequence Cleavage Domain of Preproparathyroid Hormone Alter Protein Translocation, Signal Sequence Cleavage, and Membrane-Binding Properties. Molecular Endocrinology, 1989, 3, 240-250.	3.7	19
20	A 24â€week, randomized, doubleâ€blind, activeâ€controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults. Diabetes, Obesity and Metabolism, 2019, 21, 2248-2256.	2.2	16
21	A 12â€week, randomized, doubleâ€blind, placeboâ€controlled, fourâ€arm doseâ€finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 566-573.	g 2.2	16
22	Statins, cholesterol, and the prevention of coronary heart disease. FASEB Journal, 2006, 20, 200-201.	0.2	10
23	Case 22-2019: A 65-Year-Old Woman with Weakness, Dark Urine, and Dysphagia. New England Journal of Medicine, 2019, 381, 275-283.	13.9	9
24	Targeting innate immunity for CV benefit. Drug Discovery Today: Therapeutic Strategies, 2008, 5, 15-23.	0.5	6
25	Preproparathyroid Hormone: A Model for Analyzing the Secretory Pathway. Annals of the New York Academy of Sciences, 1987, 493, 43-49.	1.8	3
26	NIH Centers for Accelerated Innovations Program: principles, practices, successes and challenges. Nature Reviews Drug Discovery, 2017, 16, 663-664.	21.5	2
27	Of mice, men and cholesterol. Hepatology, 1994, 19, 1054-1056.	3.6	O
28	An overview of the process, progress, and outcomes of a National Center for Accelerated Innovation: The Boston Biomedical Innovation Center Experience. Journal of Clinical and Translational Science, 2021, 5, e137.	0.3	0